Osiris Therapeutics Names New CFO
Osiris Therapeutics, a stem cell therapeutic company, has appointed Richard Hunt as its new CFO.
Mr Hunt will report directly to Randal Mills, president and CEO. Additionally, Philip Jacoby, Jr, the company’s controller and interim CFO, has been promoted to the position of vice president of finance.
Mr Hunt has spent 18 years in progressive leadership positions with Baxter Healthcare/American Hospital Supply, ultimately as vice president of corporate audit.
Mr Hunt holds a bachelor of science degree in accounting from Northern Illinois University and a MBA from Pepperdine University.
Dr Mills said: “Rich is an exciting addition to the Osiris management team. His extensive experience in senior leadership positions in publicly traded healthcare companies will benefit Osiris as we progress towards our now near-term goal of commercializing the world’s first stem cell drug.”